Drug Pricing Takes Over User Fee Hearing – And That Might Be Good News For Industry
Innovator companies are not generally happy when congressional committees focus on the cost of prescription drugs, particularly in hearings supposedly focused on other subjects. But when a Senate committee discussing the US FDA user fee reauthorization process devotes considerable time to the theme of pricing, it probably isn’t such a bad thing.
You may also be interested in...
Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.
Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.
The bill, some version of which is undoubtedly destined for the FDA user fee package, also would codify existing labeling guidance for products cleared through the pathway.